Displaying drugs 301 - 325 of 7378 in total
Sevelamer
Sevelamer is a phosphate binding drug used to prevent hyperphosphataemia in patients with chronic renal failure. It is marketed by Genzyme under the trade name Renagel.
Approved
Chloroquine
Chloroquine is an aminoquinolone derivative first developed in the 1940s for the treatment of malaria. It was the drug of choice to treat malaria until the development of newer antimalarials such as pyrimethamine, artemisinin, and mefloquine. Chloroquine and its derivative hydroxychloroquine have since been repurposed for the treatment of a...
Approved
Investigational
Vet approved
Matched Categories: … P-glycoprotein inhibitors ... P-glycoprotein substrates ... Cytochrome P-450 Substrates ... Cytochrome P-450 CYP3A Substrates ... Cytochrome P-450 CYP2C8 Substrates …
Simeprevir
Simeprevir is a hepatitis C virus (HCV) NS3/4A protease inhibitor indicated in patient's with HCV genotype 1 for the treatment of chronic hepatitis C virus (HCV) infection. HCV is a single-stranded RNA virus that is categorized into nine distinct genotypes, with genotype 1 being the most common in the United...
Approved
Matched Categories: … Cytochrome P-450 Substrates ... P-glycoprotein inhibitors ... P-glycoprotein substrates ... Cytochrome P-450 CYP3A Inhibitors ... Cytochrome P-450 CYP1A2 Inhibitors …
Medroxyprogesterone acetate
Medroxyprogesterone acetate (MPA) is a progesterone derivative that is more resistant to metabolism for improved pharmacokinetic properties. MPA can be use to treat secondary amenorrhea, endometrial hyperplasia, abnormal uterine bleeding, osteoporosis, vasomotor symptoms in menopause, vulvar and vaginal atrophy, prevent pregnancy, manage pain in endometriosis, prevent pregnancy, and is also...
Approved
Investigational
Matched Categories: … P-glycoprotein inhibitors ... Cytochrome P-450 Substrates ... Cytochrome P-450 CYP3A Inducers ... Cytochrome P-450 CYP3A4 Inducers ... Cytochrome P-450 Enzyme Inducers …
Resmetirom
Resmetirom is a thyroid hormone receptor-beta (THR-beta) agonist. On March 14, 2024, it was approved by the FDA as the first treatment of liver fibrosis due to noncirrhotic non-alcoholic steatohepatitis (NASH), which is a form of non-alcoholic fatty liver disease (NAFLD). Thyroid hormones directly regulate lipid metabolism in the liver;...
Approved
Investigational
Matched Categories: … Cytochrome P-450 Substrates ... Cytochrome P-450 CYP2C8 Inhibitors ... Cytochrome P-450 CYP2C8 Substrates ... Cytochrome P-450 Enzyme Inhibitors ... Cytochrome P-450 CYP2C8 Inhibitors (weak) …
Bioallethrin
Bioallethrin refers to a mixture of two of the allethrin isomers (1R,trans;1R and 1R,trans;1S) in an approximate ratio of 1:1, where both isomers are active ingredients. A mixture of the two same stereoisomers, but in an approximate ratio of R:S in 1:3, is called esbiothrin. A mixture containing only S-forms...
Approved
Experimental
Matched Categories: … Cytochrome P-450 Substrates ... Cytochrome P-450 CYP3A Substrates ... Cytochrome P-450 CYP2C8 Substrates ... Cytochrome P-450 CYP2C9 Substrates ... Cytochrome P-450 CYP2C19 Substrates …
Nortriptyline
Nortriptyline hydrochloride, the active metabolite of amitriptyline, is a tricyclic antidepressant (TCA). It is used in the treatment of major depression and is also used off-label for chronic pain and other conditions.
Approved
Matched Categories: … P-glycoprotein substrates ... Cytochrome P-450 Substrates ... Cytochrome P-450 CYP1A2 Substrates ... Cytochrome P-450 CYP3A Substrates ... Cytochrome P-450 CYP2D6 Inhibitors …
Calcitriol
Calcitriol is an active metabolite of vitamin D with 3 hydroxyl (OH) groups and is commonly referred to as 1,25-dihydroxycholecalciferol, or 1alpha,25-dihydroxyvitamin D3, 1,25-dihydroxyvitamin D3. It is produced in the body after series of conversion steps of 7-dehydrocholesterol from exposure to UV light. 7-dehydrocholesterol is converted to DB00169 (vitamin D3)...
Approved
Nutraceutical
Matched Categories: … Cytochrome P-450 Substrates ... Cytochrome P-450 CYP3A Inducers ... Cytochrome P-450 CYP3A4 Inducers ... Cytochrome P-450 CYP3A Substrates ... Cytochrome P-450 Enzyme Inducers …
Argatroban
Argatroban is a direct, selective thrombin inhibitor. The American College of Cardiologists (ACC) recommend using bivalirudin or argatroban in patients who have had, or at risk for, heparin induced thrombocytopenia (HIT) and are undergoing percutaneous coronary intervention. Argatroban is a non-heparin anticoagulant shown to both normalize platelet count in patients...
Approved
Investigational
Matched Categories: … Cytochrome P-450 Substrates ... Cytochrome P-450 CYP3A Substrates ... Cytochrome P-450 CYP3A4 Substrates ... Cytochrome P-450 CYP3A5 Substrates ... Cytochrome P-450 CYP3A4 Substrates (strength unknown) …
Buspirone
Buspirone is a novel anxiolytic agent with a unique structure and a pharmacological profile. Belonging to the azaspirodecanedione drug class, buspirone is a serotonin 5-HT1A receptor agonist that is not chemically or pharmacologically related to benzodiazepines, barbiturates, and other sedative/anxiolytic drugs. Unlike many drugs used to treat anxiety, buspirone does...
Approved
Investigational
Matched Categories: … P-glycoprotein inhibitors ... Cytochrome P-450 Substrates ... Cytochrome P-450 CYP3A Substrates ... Cytochrome P-450 CYP2D6 Substrates ... Cytochrome P-450 CYP3A4 Substrates …
Vilazodone
Vilazodone is a novel compound with combined high affinity and selectivity for the 5-hydroxytryptamine (5-HT) transporter and 5-HT(1A) receptors[Label,A177622]. Vilazodone may also be associated with less sexual dysfunction and weight gain . Vilazodone was given FDA approval on January 21, 2011[L6046,A177622].
Approved
Matched Categories: … Cytochrome P-450 Substrates ... Cytochrome P-450 CYP2D6 Inhibitors ... Cytochrome P-450 CYP3A Substrates ... Cytochrome P-450 CYP2C19 Substrates ... Cytochrome P-450 CYP2D6 Substrates …
Lynestrenol
Lynestrenol is a progestin and prodrug of norethisterone.
Approved
Investigational
Matched Categories: … Cytochrome P-450 Substrates ... Cytochrome P-450 CYP3A Substrates ... Cytochrome P-450 CYP2C19 Inhibitors ... Cytochrome P-450 CYP2C9 Substrates ... Cytochrome P-450 CYP3A4 Substrates …
Mefenamic acid
A non-steroidal anti-inflammatory agent with analgesic, anti-inflammatory, and antipyretic properties. It is an inhibitor of cyclooxygenase.
Approved
Matched Categories: … Cytochrome P-450 Substrates ... Cytochrome P-450 CYP1A2 Inhibitors ... Cytochrome P-450 CYP1A2 Substrates ... Cytochrome P-450 CYP2C8 Inhibitors ... Cytochrome P-450 CYP2C9 Inhibitors …
1,2-Benzodiazepine
Benzodiazepine is under investigation for the prevention of Delirium and C.Surgical Procedure; Cardiac. Benzodiazepine has been investigated for the treatment of Obesity, Sleep Apnea, Obstructive, and Disorders of Gallbladder, Biliary Tract and Pancrease.
Approved
Investigational
Matched Categories: … Cytochrome P-450 Substrates ... Cytochrome P-450 CYP3A Substrates ... Cytochrome P-450 CYP3A4 Substrates …
Lorpiprazole
Lorpiprazole is a serotonin antagonist and reuptake inhibitor used for the treatment of major depressive disorder. It is a piperazinyl-triazole derivative.
Approved
Matched Categories: … Cytochrome P-450 Substrates ... Cytochrome P-450 CYP2D6 Substrates ... Cytochrome P-450 CYP3A Substrates ... Cytochrome P-450 CYP3A4 Substrates …
Ropivacaine
Ropivacaine is an aminoamide local anesthetic drug marketed by AstraZeneca under the trade name Naropin. It exists as a racemate of its S- and R-enantiomers, although the marketed form is supplied only as the purified S-enantiomer.
Approved
Matched Categories: … Cytochrome P-450 Substrates ... Cytochrome P-450 CYP1A2 Substrates ... Cytochrome P-450 CYP3A Substrates ... Cytochrome P-450 CYP2B6 Substrates ... Cytochrome P-450 CYP3A4 Substrates …
Eplerenone
Eplerenone, an aldosterone receptor antagonist similar to spironolactone, has been shown to produce sustained increases in plasma renin and serum aldosterone, consistent with inhibition of the negative regulatory feedback of aldosterone on renin secretion. The resulting increased plasma renin activity and aldosterone circulating levels do not overcome the effects of...
Approved
Matched Categories: … Cytochrome P-450 Substrates ... Cytochrome P-450 CYP3A Substrates ... Cytochrome P-450 CYP3A4 Substrates ... Cytochrome P-450 CYP3A5 Substrates ... Cytochrome P-450 CYP3A7 Substrates …
Ibrutinib
Ibrutinib is a small molecule that acts as an irreversible potent inhibitor of Burton's tyrosine kinase. It is designated as a targeted covalent drug and presented as a promising activity in B-cell malignancies in clinical trials. Ibrutinib was developed by Pharmacyclics Inc and was first approved by the FDA in...
Approved
Matched Categories: … Cytochrome P-450 Substrates ... Cytochrome P-450 CYP3A Substrates ... Cytochrome P-450 CYP2D6 Substrates ... Cytochrome P-450 CYP3A4 Substrates ... Cytochrome P-450 CYP3A5 Substrates …
Fluorometholone
A glucocorticoid employed, usually as eye drops, in the treatment of allergic and inflammatory conditions of the eye. It has also been used topically in the treatment of various skin disorders. (From Martindale, The Extra Pharmacopoeia, 30th ed, p732)
Approved
Investigational
Matched Categories: … Cytochrome P-450 Substrates ... Cytochrome P-450 CYP3A Inducers ... Cytochrome P-450 CYP3A4 Inducers ... Cytochrome P-450 CYP3A5 Inducers ... Cytochrome P-450 CYP3A Substrates …
Pomalidomide
Pomalidomide, an analogue of thalidomide, is an immunomodulatory antineoplastic agent. FDA approved on February 8, 2013.
Approved
Matched Categories: … P-glycoprotein substrates ... Cytochrome P-450 Substrates ... Cytochrome P-450 CYP1A2 Substrates ... Cytochrome P-450 CYP3A Substrates ... Cytochrome P-450 CYP3A4 Substrates …
Disulfiram
A carbamate derivative used as an alcohol deterrent. It is a relatively nontoxic substance when administered alone, but markedly alters the intermediary metabolism of alcohol. When alcohol is ingested after administration of disulfiram, blood acetaldehyde concentrations are increased, followed by flushing, systemic vasodilation, respiratory difficulties, nausea, hypotension, and other symptoms...
Approved
Matched Categories: … Cytochrome P-450 Substrates ... Cytochrome P-450 CYP3A Substrates ... Cytochrome P-450 CYP2E1 Inhibitors ... Cytochrome P-450 CYP3A4 Substrates ... Cytochrome P-450 CYP3A5 Substrates …
Memantine
Initially approved by the FDA in 2013, memantine is an N-methyl-D-aspartate (NMDA) receptor antagonist used in the management of Alzheimer's Disease (AD). It is different from many other Alzheimer's Disease medications, as it works by a different mechanism than the cholinesterase enzyme inhibitors normally employed in the management of Alzheimer's...
Approved
Investigational
Matched Categories: … Cytochrome P-450 CYP2A6 Inhibitors ... Cytochrome P-450 CYP2B6 Inhibitors ... Cytochrome P-450 Enzyme Inhibitors ... Cytochrome P-450 CYP2C19 Inhibitors ... Cytochrome P-450 CYP2A6 Inhibitors (weak) …
Corticotropin
Corticotropin (ACTH or adrenocorticotropic hormone) is a polypeptide hormone produced and secreted by the pituitary gland. It is an important player in the hypothalamic-pituitary-adrenal axis.
Approved
Investigational
Vet approved
Matched Categories: … Cytochrome P-450 Substrates ... Cytochrome P-450 CYP3A Inducers ... Cytochrome P-450 CYP3A4 Inducers ... Cytochrome P-450 CYP3A Substrates ... Cytochrome P-450 Enzyme Inducers …
Daridorexant
Daridorexant, formerly known as nemorexant, is a selective dual orexin receptor antagonist used to treat insomnia. Insomnia is characterized by difficulties with sleep onset and/or sleep maintenance and impairment of daytime functioning. It chronically affects the person's daily functioning and long-term health effects, as insomnia is often associated with comorbidities...
Approved
Matched Categories: … Cytochrome P-450 Substrates ... Cytochrome P-450 CYP3A Substrates ... Cytochrome P-450 CYP3A4 Substrates …
Torasemide
Torasemide is a high-ceiling loop diuretic. Structurally, it is a pyridine-sulfonylurea used as an antihypertensive agent. Torasemide was first approved for clinical use by the FDA in 1993.
Approved
Matched Categories: … Cytochrome P-450 Substrates ... Cytochrome P-450 CYP2C8 Substrates ... Cytochrome P-450 CYP2C9 Inhibitors ... Cytochrome P-450 CYP2C9 Substrates ... Cytochrome P-450 Enzyme Inhibitors …
Displaying drugs 301 - 325 of 7378 in total